Parabilis CEO reports stock option holdings
Parabilis Medicines, Inc. director and President & CEO Mammen Mathai filed an initial ownership report detailing several stock option awards over common stock.
Rhea-AI Filing Summary
Parabilis Medicines, Inc. director and President & CEO Mammen Mathai filed an initial ownership report detailing several stock option awards over common stock. The filing lists options with exercise prices of $1.48, $3.14, and $3.43 per share, expiring between 2033 and 2036. Footnotes explain that these options vest in monthly installments, in some cases starting in March 2024 and February 2026, with one grant also contingent on achieving specified performance objectives and continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Mammen Mathai
Role
President & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 5,834,955 contracts (Direct)
Footnotes (4)
- F1. 25% of the shares subject to this option vested and became exercisable on March 16, 2024 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F2. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 28, 2024, subject to the Reporting Person's continued service on each such vesting date.
- F3. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 28, 2024 contingent upon the achievement of certain performance objectives, subject to the Reporting Person's continued service on each such vesting date.
- F4. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 24, 2026, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Option exercise price: $3.14 per share
Underlying shares at $3.14: 2,274,351 shares
Option exercise price: $1.48 per share
+5 more
8 metrics
Option exercise price
$3.14 per share
Stock option over common stock, expires February 23, 2036
Underlying shares at $3.14
2,274,351 shares
Underlying common stock for $3.14 option grant
Option exercise price
$1.48 per share
Two stock option grants, expire March 27, 2034
Underlying shares at $1.48
590,940 shares
First $1.48 option block, time-based vesting
Underlying shares at $1.48 (performance)
592,463 shares
Second $1.48 option block, performance-contingent vesting
Option exercise price
$3.43 per share
Stock option expiring April 20, 2033
Underlying shares at $3.43
2,377,201 shares
Underlying common shares for $3.43 option grant
Initial cliff vesting
25% vested March 16, 2024
Portion of one option grant vesting before monthly installments
Key Terms
Stock Option (right to buy), underlying common stock, vest and become exercisable, performance objectives, +1 more
5 terms
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
underlying common stock financial
"underlying_security_title": "Common Stock""
vest and become exercisable financial
"The shares subject to this option shall vest and become exercisable in forty-eight"
performance objectives financial
"contingent upon the achievement of certain performance objectives, subject to the Reporting Person's continued service"
continued service financial
"subject to the Reporting Person's continued service on each such vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Parabilis Medicines (PBLS) Form 3 filing for Mammen Mathai show?
The Form 3 shows Mammen Mathai’s existing stock option holdings in Parabilis Medicines. It details multiple options over common stock, including exercise prices, expiration dates, and vesting schedules tied to continued service and, for one grant, performance objectives.
What are the key terms of the $1.48 stock options reported in the PBLS Form 3?
Two option positions carry a $1.48 exercise price, covering 590,940 and 592,463 underlying common shares. Both expire in 2034 and vest in 48 equal monthly installments starting March 28, 2024, subject to Mammen Mathai’s continued service with the company.
Are any Parabilis Medicines (PBLS) options tied to performance objectives in this filing?
Yes. One $1.48 stock option grant vests in 48 monthly installments starting March 28, 2024, but is contingent on achieving specified performance objectives. Vesting also requires Mammen Mathai’s continued service with Parabilis Medicines on each applicable vesting date.
When do Mammen Mathai’s reported Parabilis Medicines stock options expire?
The reported stock options expire on various dates in 2033, 2034, and 2036. Specifically, one grant expires April 20, 2033, two expire March 27, 2034, and another expires February 23, 2036, providing long-dated equity incentives.
How do the Parabilis Medicines (PBLS) options for Mammen Mathai vest over time?
One grant vested 25% on March 16, 2024, with the remainder vesting monthly thereafter. Others vest in 48 equal monthly installments beginning March 28, 2024, or February 24, 2026, all subject to continued service and, for one grant, performance conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
